Human Papilloma Virus Vaccination and Cervical Screening in the Italian Regions: An Overview of the Current State of the Art

Author:

Bechini Angela1ORCID,Cosma Claudia2ORCID,Di Pisa Giulia2,Fanfani Alice2,Ionita Giulia2ORCID,Liedl Davide2ORCID,Lunetta Carla2,Martorella Linda2,Mele Silvia2,Stacchini Lorenzo2ORCID,Vaccaro Gabriele2,Zuccaro Ornella3,Valente Stefano4,Prandi Gian Marco4,Bonanni Paolo1ORCID,Boccalini Sara1ORCID

Affiliation:

1. Department of Health Sciences, University of Florence, 50134 Florence, Italy

2. Medical Specialization School of Hygiene and Preventive Medicine, University of Florence, 50134 Florence, Italy

3. Department of Prevention and Public Health, Local Health Authority Asl Roma 2, 00182 Rome, Italy

4. MSD Italia Srl, 00189 Rome, Italy

Abstract

Human Papilloma Virus (HPV) infection and HPV-related cancers can be prevented through vaccinations and mass cervical screening programmes. The Ministry of Health in Italy provides recommendations on primary and secondary prevention of HPV-related diseases, but the 19 Italian regions and 2 autonomous provinces have organisational and decision-making autonomy, with differences in the strategies for offering prevention. The aim of this study is to describe the HPV vaccination and cervical screening offered in all Italian regions. Regional official documents up until 31 December 2021 were first identified. Subsequently, primary and secondary prevention experts from each region were interviewed to validate the previously collected data. The National Immunisation Plan (NIP) 2017–2019 recommends HPV vaccination from the age of 11 for both sexes, with a coverage target of 95%. HPV vaccination is offered free of charge or co-payment. All regions have screening programmes for cervical cancer, using PAP or HPV-DNA tests every three to five years. All regions have an electronic registry for vaccination and screening status. All regions have developed awareness-raising campaigns. It is important to harmonise regional policies with the implementation of information systems integration. The collected data could enhance both regional and national public health initiatives, bolstering the resilience of vaccination programs.

Funder

MSD

Publisher

MDPI AG

Reference47 articles.

1. National Cancer Institute (2024, April 27). HPV and Cancer, Available online: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer.

2. Epidemiology and Burden of HPV-Related Disease;Serrano;Best. Pract. Res. Clin. Obstet. Gynaecol.,2018

3. Immunogenicity, Efficacy, and Safety of Human Papillomavirus Vaccine: Data from China;Li;Front. Immunol.,2023

4. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA A Cancer J. Clin.,2021

5. Prophylactic Vaccination against Human Papillomaviruses to Prevent Cervical Cancer and Its Precursors;Arbyn;Cochrane Database Syst. Rev.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3